Surmodics Reports High Success Rates for Pounce Thrombectomy Device in Real-World Limb Ischemia Study
Reuters
Nov 04
Surmodics Reports High Success Rates for Pounce Thrombectomy Device in Real-World Limb Ischemia Study
Surmodics, Inc. has announced results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study. The results were presented on November 3rd at the 23rd Annual VIVA Conference in Las Vegas, Nevada. The PROWL registry is an open-label, retrospective, multi-center study in the U.S. evaluating the Surmodics Pounce™ Thrombectomy Platform for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. The analysis demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients, with over 40% experiencing symptoms for more than two weeks prior to intervention. In nearly 80% of cases, no additional clot removal was required after using the device, and procedural success exceeded 90%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SurModics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104485358) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.